We report our first case of Coronavirus disease (COVID-19) infection with hepatitis B co-infection who presented with fever, catarrh, headaches, fatigue, and loss of smell. He had a history of chronic hepatitis B infection which appeared to be inactive given a history of normal outpatient liver tests prior to admission for COVID-19. Following the positive nasopharyngeal polymerase chain reaction diagnosis with COVID-19, liver function tests revealed evidence of hepatitis with elevated bilirubin and liver enzymes and deranged full blood count findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927974 | PMC |
| http://dx.doi.org/10.4103/jfcm.JFCM_410_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 Symptoms Only Minutely Influenced by Genes Among Children in a Nationwide Twin Cohort.
Pediatr Infect Dis J
January 2025
From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: The World Health Organization classified coronavirus disease (COVID-19) as a pandemic by March 11, 2020. Children had a milder disease than adults, and many were asymptomatic. The pandemic could be seen as a natural experiment with several changes, including time spent at home.
View Article and Find Full Text PDFEffect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
PLoS Med
January 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.
View Article and Find Full Text PDFProtocol for evaluating humoral immune responses in mice following SARS-CoV-2 vaccination.
STAR Protoc
January 2025
Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong 510005, China; State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China. Electronic address:
Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.
View Article and Find Full Text PDFThermally Triggered Double Emulsion-Integrated Hydrogel Microparticles for Multiplexed Molecular Diagnostics.
Adv Sci (Weinh)
January 2025
Center for Advanced Biomolecular Recognition, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
During the COVID-19 pandemic, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) has been recognized as the most reliable diagnostic tool. However, there is a need to develop multiplexed assays capable of analyzing multiple genes simultaneously to expand its application. To address this, a multiplexed RT-qPCR using a double emulsion (DE)-based carrier and a polymer microparticle reactor, termed primer-incorporated network tailored with Taqman probe (TaqPIN) is developed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!